Abstract
Autism spectrum disorder (ASD) affects about 1 in 45 individuals in the United States, yet effective treatments are yet to be defined. There is growing evidence that ASD is associated with abnormalities in several metabolic pathways, including the inter-connected folate, methylation and glutathione pathways. Several treatments that can therapeutically target these pathways have been tested in preliminary clinical trials. The combination of methylcobalamin (mB12) with low-dose folinic acid (LDFA) and sapropterin, a synthetic form of tetrahydrobiopterin (BH4) have been studied in open-label trials while high-dose folinic acid has been studied in a double-blind placebo controlled trial. All of these treatments have the potential to positively affect folate, methylation and glutathione pathways. Although the effect of mB12/LDFA and BH4 on methylation and glutathione metabolism have been examined in the open-label studies, these changes have not been compared to controls who received a placebo in order to account for the natural variation in the changes in these pathways. Furthermore, the recent study using high-dose folinic acid (HDFA) did not analyze the change in metabolism resulting from the treatment. Thus, we compared changes in methylation and glutathione metabolism and biomarkers of chronic oxidative stress as a result of these three treatments to individuals receiving placebo. In general, mB12/LDFA treatment had a significant effect on glutathione and cysteine metabolism with a medium effect size while BH4 had a significant effect on methylation and markers of chronic oxidative stress with a large effect size. HDFA treatment did not significantly influence biomarkers of methylation, glutathione or chronic oxidative stress. One caveat was that participants in the mB12/LDFA and BH4 studies had significantly worse markers of glutathione metabolism and chronic oxidative stress at baseline, respectively. Thus, the participants selected in these two clinical trials may have been those with the most severe metabolic abnormalities and most expected to respond to these treatments. Overall this study supports the notion that metabolic abnormalities in individuals with ASD may be amenable to targeted treatments and provide some insight into the mechanism of action of these treatments.
Highlights
Autism spectrum disorder (ASD) is a behaviorally defined disorder that is estimated to affect up to 1 in 45 individuals in the United States (Zablotsky et al, 2014)
Abnormalities which have been verified in multiple studies include impairments in mitochondrial function (Frye and Rossignol, 2011; Rossignol and Frye, 2012a,b), abnormalities in key nutrients and cofactors such as carnitine (Gargus and Lerner, 1997; Filipek et al, 2004; Celestino-Soper et al, 2012; Frye et al, 2013d), folate (Frye et al, 2013e), and tetrahydrobiopterin (Frye, 2010; Frye et al, 2010, 2013b) as well as oxidative stress with associated abnormalities in glutathione-mediated redox regulation (James et al, 2004, 2006, 2009b; Rose et al, 2012a,b; Frye et al, 2013a)
In this study we examined three clinical treatments that have the potential to influence methylation and redox regulation pathways as well as positively affect oxidative stress
Summary
Autism spectrum disorder (ASD) is a behaviorally defined disorder that is estimated to affect up to 1 in 45 individuals in the United States (Zablotsky et al, 2014). What is hopeful about abnormalities in metabolic pathways is that metabolic abnormalities often can be corrected with well-tolerated treatments that either replace key metabolites or provide intermediates that by-pass the metabolic block (Frye and Rossignol, 2014, 2016; Niyazov et al, 2016; Delhey et al, 2017). Such treatments could substantially improve the lives of children with ASD as they target pathophysiological abnormalities, correcting underlying abnormalities in faulty biological processes rather than treating symptoms
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
